Regencell Bioscience Holdings, a small Hong Kong-based biotech focused on traditional Chinese medicine treatments for neurocognitive disorders, experienced an unprecedented stock surge of up to 82,000% in 2025. The rally was driven by speculative retail buying, fuelled by a 38-for-1 stock split and social media hype, without any new clinical or regulatory developments. After peaking with a market cap of $33 billion, shares plunged 74% within days yet remained up 13,000% year-to-date, highlighting extreme volatility and raising concerns regarding market speculation in biotech stocks without underlying scientific validation.